04 Apr, 2022 New Results from HELIOS-A Phase 3 Study of Vutrisiran Presented at ACC
New results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic, in hereditary transthyretin-mediated (hATTR) amyloidosis patients with polyneuropathy, were presented during a poster presentation at the 71st Annual Meeting of the American College of Cardiology (ACC) held April 2–4, 2022. The data help further our understanding of the safety and efficacy of vutrisiran in patients with hATTR amyloidosis with polyneuropathy who have variants that have previously been associated with predominant cardiomyopathy.
González-Duarte, et al. “HELIOS-A: Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy”